So far, Germany, France, Poland and the Czech Republic have announced opposition to the European Commission's plan that would oblige all EU member states to consider joint EU clinical assessments for certain high-risk medical devices, as well as pharmaceuticals. One of the main points of opposition from the authorities is that mandatory joint health technology assessments (HTAs) would encroach on the national competencies of member states.
Now, the device industry is also voicing its opposition to the HTA proposal, but for its own reasons. Medtech representatives say it not in the best interests of industry, innovation,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?